• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

peartherapeutics

Pear Therapeutics to go public via merger with SPAC

June 22, 2021 By Sean Whooley

Pear Therapeutics

Prescription digital therapeutics pioneer Pear Therapeutics announced today that it will go public by merging with a SPAC called Thimble Point Acquisition Corp. Boston-based Pear Therapeutics’ combination with the special purpose acquisition company (SPAC), whose management team is associated with the Pritzker Vlock Family Office, will result in a combined company named Pear Holdings Corp. […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Mergers & Acquisitions, Neurological, Patient Monitoring, Pharmaceuticals, Wall Street Beat Tagged With: Pear Therapeutics, peartherapeutics, Thimble Point Acquisition Corp.

Pear Therapeutics inks multiple agreements to expand digital therapeutic platform

April 6, 2021 By Sean Whooley

Pear Therapeutics

Pear Therapeutics announced today that it entered into multiple agreements to bolster its prescription digital therapeutics (PDT) platform. Boston-based Pear Therapeutics’ agreements are set to add to its library of digital biomarkers, machine learning algorithms, sensor-based technologies and digital therapeutics, according to a news release. The agreements have been struck with technology companies including Empatica, […]

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Neurological, Patient Monitoring, Pharmaceuticals Tagged With: Empatica, etectrx, KeyWise, peartherapeutics

Prescryptive to offer benefit coverage for Pear Therapeutics opioid use disorder treatments

April 2, 2021 By Sean Whooley

Pear Therapeutics Prescryptive Health

Pear Therapeutics announced today that Prescryptive Health will offer and administer benefit coverage for its digital therapeutics. Boston-based Pear Therapeutics’ reSET and reSET-O, two FDA-cleared prescription digital therapeutics (PDTs) for treating substance and opioid use disorder, have been added to Prescryptive’s formularies and are being administered as standard pharmacy benefits for its members, according to […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Patient Monitoring, Pharmaceuticals Tagged With: peartherapeutics, Prescryptive Health

Pear Therapeutics touts cost-effectiveness of opioid use disorder treatment

February 23, 2021 By Sean Whooley

Pear Therapeutics

Pear Therapeutics today touted analysis of its reSET-O therapeutic for opioid use disorder (OUD) that demonstrated cost-effectiveness. Boston-based Pear Therapeutics’ reSET-O is the first and only FDA-authorized prescription digital therapeutic for treating OUD, according to a news release. The analysis, published in Postgraduate Medicine, highlighted that reSET-O and treatment-as-usual (which includes transmucosal buprenorphine, face-to-face counseling […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: opioids, peartherapeutics

Pear Therapeutics closes $80M Series D

December 9, 2020 By Sean Whooley

Pear Therapeutics

Substance use and opioid use treatment developer Pear Therapeutics announced that it closed an $80 million Series D financing round. Existing investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox and EDBI contributed, as did new investors Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management, according to a news […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup Tagged With: Novartis, opioids, peartherapeutics

Novartis unit spikes Pear Therapeutics deal

October 17, 2019 By Sean Whooley

Pear Therapeutics

Novartis (NYSE:NVS) unit Sandoz said this week that Pear Therapeutics will take sole responsibility for the commercialization of their prescription digital therapeutics program for treating substance and opioid use disorders. In April 2018, Pear announced that it agreed to deal commercialization rights of its digital therapeutics to Sandoz. The companies did not disclose financial details, but […]

Filed Under: Business/Financial News, Featured, Pharmaceuticals Tagged With: Novartis, peartherapeutics, sandoz

Pear Therapeutics closes $64m Series C round

January 9, 2019 By Sarah Faulkner

Pear Therapeutics logo updated

Pear Therapeutics said this month that it closed a $64 million Series C round led by Temasek. The Boston-based company plans to use its newly-acquired funds to support the global commercialization of its reSET prescription digital therapeutics and fund its clinical pipeline, as well as buy up additional assets. Other investors in the round include […]

Filed Under: Business/Financial News, Featured, Funding Roundup, mHealth (Mobile Health), Pain Management Tagged With: peartherapeutics

Sandoz, Pear launch digital therapy for opioid use disorder

January 8, 2019 By Sarah Faulkner

Pear Therapeutics logo updated

Novartis (NYSE:NVS) division Sandoz and Pear Therapeutics this week kicked off the U.S. commercial launch of the first FDA-cleared prescription digital therapy for people with opioid use disorder. The companies partnered to commercialize a 12-week cognitive behavioral therapy intended to be used in tandem with outpatient treatment. The therapy includes transmucosal buprenorphine and contingency management designed to reinforce […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals Tagged With: peartherapeutics, sandoz

Pear Therapeutics, Sandoz ink deal for prescription digital therapeutics

April 19, 2018 By Sarah Faulkner

Pear Therapeutics

Pear Therapeutics revealed yesterday that it agreed to deal commercialization rights of its digital therapeutics to Novartis (NYSE:NVS) division Sandoz. The company’s reSET substance use disorder therapy became the first prescription digital therapeutic approved by the FDA in September last year. reSET-O, a digital therapeutic designed for people suffering from opioid use disorder, is under review […]

Filed Under: Business/Financial News, Featured, mHealth (Mobile Health), Patient Monitoring, Wall Street Beat Tagged With: Novartis, peartherapeutics, sandoz

Pear Therapeutics raises $50m for digital substance use disorder therapies

January 2, 2018 By Sarah Faulkner

Pear Therapeutics

Pear Therapeutics said today that it closed a $50 million Series B round to help commercialize its prescription digital substance abuse therapies. Temasek led the round and was joined by 5AM Ventures, Jazz Venture Partners, Novartis (NYSE:NVS) and others. In September, the company’s reSET therapy became the first prescription digital therapeutic approved by the FDA. One […]

Filed Under: Drug-Device Combinations, Featured, mHealth (Mobile Health), Pharmaceuticals Tagged With: Novartis, peartherapeutics

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS